We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Change in Polycythemia Vera Treatment: Ropeginterferon Alfa-2b in Light of Current Trials.
- Authors
Gisslinger, Heinz
- Abstract
Ropeginterferon alfa-2b (RopegIFN) enables effective cytoreduction in polycythemia vera (PV). Recent analyses suggest that long-term RopegIFN therapy fulfills treatment goals important to patients with PV including good quality of life, the slowing of disease progression, and long event-free survival. Data support the use of RopegIFN in both early PV therapy and second-line and beyond.
- Subjects
THERAPEUTIC use of interferons; DISEASE progression; POLYCYTHEMIA vera; CLINICAL drug trials; HYDROXYUREA; GLOBAL burden of disease; TREATMENT duration; PATIENT-centered care; TREATMENT effectiveness; INTERFERONS; QUALITY of life; PROGRESSION-free survival; EVALUATION
- Publication
Turkish Journal of Hematology, 2023, Vol 40, Issue 4, p266
- ISSN
1300-7777
- Publication type
Article
- DOI
10.4274/tjh.galenos.2023.2023.0419